Xencor Inc (XNCR) — SEC Filings
Xencor Inc (XNCR) — 45 SEC filings. Latest: 10-Q (Nov 5, 2025). Includes 16 8-K, 15 SC 13G/A, 6 10-Q.
Overview
Xencor Inc (XNCR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Xencor Inc. reported a significant increase in revenue from collaborations, milestones, and royalties, reaching $97.339 million for the nine months ended September 30, 2025, up from $57.700 million in the same period of 2024, representing a 68.7% increase. This was primarily driven by a substantial
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Xencor Inc is neutral.
Filing Type Overview
Xencor Inc (XNCR) has filed 6 10-Q, 16 8-K, 2 DEF 14A, 1 8-K/A, 2 10-K, 1 10-K/A, 15 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of XNCR's 29 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $97,339,000 |
| Net Income | -$85,270,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $28,291,000 |
| Operating Margin | N/A |
| Total Assets | $868,811,000 |
| Total Debt | N/A |
Key Executives
- Dahiyat
- Desjarlais
- Eckert
- Valente
- Cornelissen
- PEO
- Dr. John Orwin
- Bassil Dahiyat
- Ms. Karen Smith
- Abigail P. Johnson
Industry Context
Xencor operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on engineered antibody therapeutics for cancer and autoimmune diseases. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and strategic partnerships to navigate the path to commercialization.
Top Tags
corporate-governance (5) · amendment (5) · sec-filing (4) · disclosure (4) · 10-Q (4) · institutional-ownership (4) · Pharmaceuticals (3) · 8-k (3) · financials (3) · 8-K (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue from collaborations, milestones, and royalties | $97.339M | Increased from $57.700M in 2024 for the nine months ended September 30, 2025 |
| Net loss attributable to Xencor Inc. | $85.270M | Reduced from $187.065M in 2024 for the nine months ended September 30, 2025 |
| Reduction in net loss | 54.4% | Percentage decrease in net loss attributable to Xencor Inc. year-over-year |
| Gain on marketable equity securities, net | $50.109M | For the nine months ended September 30, 2025, compared to a $0.448M loss in 2024 |
| Cash and cash equivalents | $28.291M | As of September 30, 2025, down from $40.875M at December 31, 2024 |
| Total assets | $868.811M | As of September 30, 2025, down from $951.945M at December 31, 2024 |
| Research and development expenses | $174.610M | For the nine months ended September 30, 2025, a slight decrease from $176.630M in 2024 |
| Common stock shares outstanding | 71,410,469 | As of October 30, 2025 |
| Q2 2025 Revenue | $15.2M | 60.5% decrease from Q2 2024 |
| Q2 2025 Net Loss | $45.8M | Widened from $22.1M in Q2 2024 |
| Q2 2025 R&D Expenses | $55.3M | Increased from $48.9M in Q2 2024 |
| Cash and Cash Equivalents | $450.5M | As of June 30, 2025, providing operational runway |
| Revenue Decrease | 60.5% | Year-over-year decline in Q2 revenue |
| SEC File Number | 001-36182 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification Number | 20-1622502 | Unique identifier for tax purposes. |
Forward-Looking Statements
- {"claim":"PRIMECAP Management Company will likely maintain a significant stake in Xencor Inc. for the foreseeable future.","entity":"PRIMECAP Management Company","targetDate":"December 31, 2024","confidence":"high"}
- {"claim":"FMR LLC will continue to hold a significant, but potentially fluctuating, stake in Xencor Inc. as part of its diversified portfolio.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Xencor Inc (XNCR)?
Xencor Inc has 45 recent SEC filings from Jan 2024 to Nov 2025, including 16 8-K, 15 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XNCR filings?
Across 45 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Xencor Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xencor Inc (XNCR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xencor Inc?
Key financial highlights from Xencor Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XNCR?
The investment thesis for XNCR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xencor Inc?
Key executives identified across Xencor Inc's filings include Dahiyat, Desjarlais, Eckert, Valente, Cornelissen and 5 others.
What are the main risk factors for Xencor Inc stock?
Of XNCR's 29 assessed filings, 1 were flagged high-risk, 10 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Xencor Inc?
Recent forward-looking statements from Xencor Inc include guidance on {"claim":"PRIMECAP Management Company will likely maintain a significant stake in Xencor Inc. for the foreseeable future and 1 other predictions.